Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy
International Journal of Clinical Oncology · 2026
DOI: 10.1007/s10147-026-03115-x ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Takeshi Sasaki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Neutrophils, Carcinoma, Renal Cell, Lymphocytes, Kidney Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mie University.
Abstract (Originalsprache)
Background
This study investigated whether neutrophil-to-lymphocyte ratio (NLR) kinetics, including changes within the first week after the initiation of first-line combination immunotherapy, are associated with overall survival (OS) in patients with advanced renal cell carcinoma (aRCC).
Methods
Consecutive patients with aRCC treated with first-line immune checkpoint inhibitor combination therapy at 12 Japanese institutions were included in this retrospective study. The NLR was assessed at baseline (BL), within 7 days (D7), and 1 month (M1) after treatment initiation. Patients were classified into three groups according to NLR at BL and at D7 as follows: BL NLR low (< 3), NLR high-low (BL NLR ≥ 3 and D7 NLR < 3), and NLR high-high (BL NLR ≥ 3 and D7 NLR ≥ 3) groups.
Results
In total, 198 patients were included in the study, with a median follow-up of 18.0 months. The median NLR changed during follow-up at BL, D7, and M1 (BL, 3.28; D7, 3.23; M1, 2.74). OS stratified by NLR at each time point was significant at BL and D7, but not at M1. Among patients with BL NLR ≥ 3 (55%, n = 109), 26 patients (24%) had D7 NLR < 3. The 2 year OS rates were 83.7, 85.5, and 66.0% for patients in the low-, high-low-, and high-high groups, respectively. Multivariate analysis revealed that high NLR was an independent risk factor associated with worse OS.
Conclusions
The combination of BL NLR and D7 NLR identified high-risk patients with aRCC treated with first-line immune checkpoint inhibitor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
- Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
- Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
- Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.
- Department of Urology, Gifu Prefectural General Medical Center, Gifu, Japan.
- Department of Urology, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan.
Förderung
- Mie University
Zitieren
APA
Sasaki, T., Higashi, S., Nishikawa, K., Iinuma, K., Nakane, K., Taniguchi, T., Sano, Y., Matsuyama, A., Ozawa, K., Tochigi, K., Tamura, M., Kubota, Y., Akamatsu, S., Koie, T., & Inoue, T. (2026). Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03115-x
Vancouver
Sasaki T, Higashi S, Nishikawa K, Iinuma K, Nakane K, Taniguchi T, et al. Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03115-x
BibTeX
@article{Sasaki2026,
author = {Sasaki, Takeshi and Higashi, Shinichiro and Nishikawa, Kouhei and Iinuma, Koji and Nakane, Keita and Taniguchi, Tomoki and Sano, Yuta and Matsuyama, Aika and Ozawa, Kaori and Tochigi, Kosuke and Tamura, Masataka and Kubota, Yasuaki and Akamatsu, Shusuke and Koie, Takuya and Inoue, Takahiro},
title = {Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy},
journal = {International Journal of Clinical Oncology},
year = {2026},
doi = {10.1007/s10147-026-03115-x}
}
EUVIMED